BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil. 2013;19:25-35. [PMID: 23350044 DOI: 10.5056/jnm.2013.19.1.25] [Cited by in Crossref: 177] [Cited by in F6Publishing: 153] [Article Influence: 19.7] [Reference Citation Analysis]
Number Citing Articles
1 Cook EK, Satake N, Sykes BW, Bennett EL, Mills PC. Pharmacokinetics of esomeprazole following intravenous and oral administration in healthy dogs. Vet Med (Auckl) 2016;7:123-31. [PMID: 30050845 DOI: 10.2147/VMRR.S112643] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Min JY, Ocampo CJ, Stevens WW, Price CPE, Thompson CF, Homma T, Huang JH, Norton JE, Suh LA, Pothoven KL, Conley DB, Welch KC, Shintani-Smith S, Peters AT, Grammer LC 3rd, Harris KE, Hulse KE, Kato A, Modyanov NN, Kern RC, Schleimer RP, Tan BK. Proton pump inhibitors decrease eotaxin-3/CCL26 expression in patients with chronic rhinosinusitis with nasal polyps: Possible role of the nongastric H,K-ATPase. J Allergy Clin Immunol 2017;139:130-141.e11. [PMID: 27717558 DOI: 10.1016/j.jaci.2016.07.020] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 6.3] [Reference Citation Analysis]
3 Launois C, Mulette P, Ancel J, Dury S, Hagenburg J, Lebargy F, Dormoy V, Deslee G, Perotin JM. [Treatment of GERD in asthma]. Rev Mal Respir 2021:S0761-8425(21)00234-5. [PMID: 34016495 DOI: 10.1016/j.rmr.2021.04.013] [Reference Citation Analysis]
4 Yang H, Juang S, Liao K. Proton pump inhibitors use and risk of chronic kidney disease in diabetic patients. Diabetes Research and Clinical Practice 2019;147:67-75. [DOI: 10.1016/j.diabres.2018.11.019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
5 Cho YK, Choi MG, Choi SC, Lee KM, Kim TO, Park SH, Moon JS, Lim YJ, Kang DH, Cheon GJ, Baik GH, Kim KO, Cho KB, Jang JS, Park JJ, Son BK, Jung HK, Kim BW, Kim SK, Lee ST, Cha JM, Kim AR, Kim EJ, Park HW, Song GS. Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer. Aliment Pharmacol Ther 2020;52:789-97. [PMID: 32701188 DOI: 10.1111/apt.15865] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
6 Strickland M, Ehrlich LS, Watanabe S, Khan M, Strub MP, Luan CH, Powell MD, Leis J, Tjandra N, Carter CA. Tsg101 chaperone function revealed by HIV-1 assembly inhibitors. Nat Commun 2017;8:1391. [PMID: 29123089 DOI: 10.1038/s41467-017-01426-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
7 Emery H, Butt TM, Coates CJ. Nutraceutical intervention protects against bacterial and chemical-induced gastrotoxicity in a non-mammalian model, Galleria mellonella. Food Chem Toxicol 2021;154:112354. [PMID: 34146620 DOI: 10.1016/j.fct.2021.112354] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Brilhante RS, da Rocha MG, de Oliveira JS, España JD, Pereira VS, Scm Castelo-Branco D, A Pereira-Neto W, Sidrim JJ, A Cordeiro R, Rocha MF. Proton pump inhibitors versus Cryptococcus species: effects on in vitro susceptibility and melanin production. Future Microbiol 2019;14:489-97. [PMID: 31033338 DOI: 10.2217/fmb-2018-0340] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
9 Tian C, Zhu L, Yu D, Cao Z, Kang T, Zhu R. The Stereoselectivity of CYP2C19 on R- and S-isomers of Proton Pump Inhibitors. Chem Biol Drug Des 2014;83:610-21. [DOI: 10.1111/cbdd.12274] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
10 Gomez-Sanchez R, Besley S, Zeliku Z, Young RJ. Method Development and Application of an Accelerated Solution Stability Screen for Drug Discovery. SLAS Discov 2020;25:1191-6. [PMID: 32522054 DOI: 10.1177/2472555220931795] [Reference Citation Analysis]
11 Li R, Chai X, Cui X, Jiang Y, Zhang D, Wang T. A fluorescence resonance energy transfer based pH probe for visualizing acidification in fungal cells. Sensors and Actuators B: Chemical 2018;274:533-40. [DOI: 10.1016/j.snb.2018.07.134] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
12 Kim HJ, Kim N, Park JH, Choi S, Shin CM, Lee OJ. Helicobacter pylori Eradication Induced Constant Decrease in Interleukin- 1B Expression over More Than 5 Years in Patients with Gastric Cancer and Dysplasia. Gut Liver 2020;14:735-45. [PMID: 32703913 DOI: 10.5009/gnl19312] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 El Rouby N, Lima JJ, Johnson JA. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opin Drug Metab Toxicol. 2018;14:447-460. [PMID: 29620484 DOI: 10.1080/17425255.2018.1461835] [Cited by in Crossref: 48] [Cited by in F6Publishing: 36] [Article Influence: 12.0] [Reference Citation Analysis]
14 Li H, Shi FH, Liu F, Chen H, Wang YQ, Gong XJ, Wei JF. H+/K+-ATPase inhibitors and acid-related disorders. Shijie Huaren Xiaohua Zazhi 2014; 22(15): 2073-2080 [DOI: 10.11569/wcjd.v22.i15.2073] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
15 Walsh M, Fais S, Spugnini EP, Harguindey S, Abu Izneid T, Scacco L, Williams P, Allegrucci C, Rauch C, Omran Z. Proton pump inhibitors for the treatment of cancer in companion animals. J Exp Clin Cancer Res 2015;34:93. [PMID: 26337905 DOI: 10.1186/s13046-015-0204-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
16 Escoffier J, Arnaud B, Kaba M, Hograindleur JP, Le Blévec E, Martinez G, Stévant I, Ray PF, Arnoult C, Nef S. Pantoprazole, a proton-pump inhibitor, impairs human sperm motility and capacitation in vitro. Andrology 2020;8:1795-804. [PMID: 32609951 DOI: 10.1111/andr.12855] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Prabhakara C, Godbole R, Sil P, Jahnavi S, Gulzar SE, van Zanten TS, Sheth D, Subhash N, Chandra A, Shivaraj A, Panikulam P, U I, Nuthakki VK, Puthiyapurayil TP, Ahmed R, Najar AH, Lingamallu SM, Das S, Mahajan B, Vemula P, Bharate SB, Singh PP, Vishwakarma R, Guha A, Sundaramurthy V, Mayor S. Strategies to target SARS-CoV-2 entry and infection using dual mechanisms of inhibition by acidification inhibitors. PLoS Pathog 2021;17:e1009706. [PMID: 34252168 DOI: 10.1371/journal.ppat.1009706] [Reference Citation Analysis]
18 Rouphael Y, Raimondi G, Lucini L, Carillo P, Kyriacou MC, Colla G, Cirillo V, Pannico A, El-Nakhel C, De Pascale S. Physiological and Metabolic Responses Triggered by Omeprazole Improve Tomato Plant Tolerance to NaCl Stress. Front Plant Sci 2018;9:249. [PMID: 29535755 DOI: 10.3389/fpls.2018.00249] [Cited by in Crossref: 38] [Cited by in F6Publishing: 25] [Article Influence: 9.5] [Reference Citation Analysis]
19 Minalyan A, Gabrielyan L, Scott D, Jacobs J, Pisegna JR. The Gastric and Intestinal Microbiome: Role of Proton Pump Inhibitors. Curr Gastroenterol Rep. 2017;19:42. [PMID: 28733944 DOI: 10.1007/s11894-017-0577-6] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 8.8] [Reference Citation Analysis]
20 Kis O, Walmsley SL, Bendayan R. In Vitro and In Situ Evaluation of pH-Dependence of Atazanavir Intestinal Permeability and Interactions with Acid-Reducing Agents. Pharm Res 2014;31:2404-19. [DOI: 10.1007/s11095-014-1336-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
21 Liu J, Huang N, Li N, Liu SN, Li MH, Li H, Luo XY, Wang YT, Li LM, Zou Q, Liu Y, Yang T. 2-(1H-Benzimidazol-2-yl)-4,5,6,7-tetrahydro-2H-indazol-3-ol, a benzimidazole derivative, inhibits T cell proliferation involving H+/K+-ATPase inhibition. Molecules 2014;19:17173-86. [PMID: 25347460 DOI: 10.3390/molecules191117173] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
22 Chen Y, Liu B, Glass K, Du W, Banks E, Kirk M. Use of Proton Pump Inhibitors and the Risk of Hospitalization for Infectious Gastroenteritis. PLoS One 2016;11:e0168618. [PMID: 27997598 DOI: 10.1371/journal.pone.0168618] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
23 Wu L, Liu J, Zheng Y, Zhai Y, Lin M, Wu G, Lv D, Shentu J. Pharmacokinetic/Pharmacodynamic Evaluation of Dexlansoprazole Infusion Injection Compared with Lansoprazole in Healthy Chinese Adults. Clin Drug Investig 2019;39:953-65. [PMID: 31338800 DOI: 10.1007/s40261-019-00824-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
24 Marinescu M, Cinteză LO, Marton GI, Chifiriuc MC, Popa M, Stănculescu I, Zălaru CM, Stavarache CE. Synthesis, density functional theory study and in vitro antimicrobial evaluation of new benzimidazole Mannich bases. BMC Chem 2020;14:45. [PMID: 32724899 DOI: 10.1186/s13065-020-00697-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
25 Yu D, Wang T, Liang Y, Liu J, Zheng J, Chen M, Wei Y. Delivery and effects of proton pump inhibitor on anaerobic digestion of food and kitchen waste under ammonia stress. J Hazard Mater 2021;416:126211. [PMID: 34492971 DOI: 10.1016/j.jhazmat.2021.126211] [Reference Citation Analysis]
26 Helgadottir H, Bjornsson ES. Problems Associated with Deprescribing of Proton Pump Inhibitors. Int J Mol Sci 2019;20:E5469. [PMID: 31684070 DOI: 10.3390/ijms20215469] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
27 Makunts T, Cohen IV, Awdishu L, Abagyan R. Analysis of postmarketing safety data for proton-pump inhibitors reveals increased propensity for renal injury, electrolyte abnormalities, and nephrolithiasis. Sci Rep 2019;9:2282. [PMID: 30783195 DOI: 10.1038/s41598-019-39335-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 8.7] [Reference Citation Analysis]
28 Nagase M, Shimada H, Nii M, Ueda S, Higashimori M, Ichikawa K, Zhang L, Zhou L, Chen Y, Zhou D, Dunyak J, Al-Huniti N. Population pharmacokinetic analysis of esomeprazole in Japanese subjects with various CYP2C19 phenotypes. J Clin Pharm Ther 2020;45:1030-8. [PMID: 32227647 DOI: 10.1111/jcpt.13129] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Zhou JH, Liu BR. Proton pump inhibitors. Shijie Huaren Xiaohua Zazhi 2013; 21(29): 3083-3088 [DOI: 10.11569/wcjd.v21.i29.3083] [Reference Citation Analysis]
30 Remes-Troche JM, García García FD, Rojas-Loureiro G, Rivera-Gutiérrez X, Reyes-Huerta J, Amieva-Balmori M. Intragastric pH effect of 20mg of levo-pantoprazole versus 40mg of racemic pantoprazole the first seven days of treatment in patients with gastroesophageal reflux disease. Rev Gastroenterol Mex (Engl Ed) 2020;85:48-55. [PMID: 31104856 DOI: 10.1016/j.rgmx.2019.02.006] [Reference Citation Analysis]
31 Yucel E, Sancar M, Yucel A, Okuyan B. Adverse drug reactions due to drug–drug interactions with proton pump inhibitors: assessment of systematic reviews with AMSTAR method. Expert Opinion on Drug Safety 2016;15:223-36. [DOI: 10.1517/14740338.2016.1128413] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
32 Shiotani A, Katsumata R, Gouda K, Fukushima S, Nakato R, Murao T, Ishii M, Fujita M, Matsumoto H, Sakakibara T. Hypergastrinemia in Long-Term Use of Proton Pump Inhibitors. Digestion 2018;97:154-62. [DOI: 10.1159/000484688] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
33 Stewart DB, Hegarty JP. Correlation between virulence gene expression and proton pump inhibitors and ambient pH in Clostridium difficile: results of an in vitro study. Journal of Medical Microbiology 2013;62:1517-23. [DOI: 10.1099/jmm.0.059709-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
34 Yang X, Li Y, Sun Y, Zhang M, Guo C, Mirza IA, Li Y. Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases. Dig Dis Sci 2018;63:302-11. [DOI: 10.1007/s10620-017-4866-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
35 Moraes-filho JP, Pedroso M, Quigley EMM; PAMES Study Group. Randomised clinical trial: daily pantoprazole magnesium 40 mg vs. esomeprazole 40 mg for gastro-oesophageal reflux disease, assessed by endoscopy and symptoms. Aliment Pharmacol Ther 2014;39:47-56. [DOI: 10.1111/apt.12540] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
36 Liang CM, Kuo MT, Hsu PI, Kuo CH, Tai WC, Yang SC, Wu KL, Wang HM, Yao CC, Tsai CE, Wang YK, Wang JW, Huang CF, Wu DC, Chuah SK, Taiwan Acid-Related Disease Study Group. First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease. World J Gastroenterol 2017; 23(47): 8395-8404 [PMID: 29307999 DOI: 10.3748/wjg.v23.i47.8395] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
37 Wolfes J, Ellermann C, Burde S, Leitz P, Bögeholz N, Willy K, Fehr M, Eckardt L, Frommeyer G. Concomitant Treatment with Proton Pump Inhibitors and Cephalosporins Does Not Enhance QT-Associated Proarrhythmia in Isolated Rabbit Hearts. Cardiovasc Toxicol 2020;20:531-8. [PMID: 32500385 DOI: 10.1007/s12012-020-09577-3] [Reference Citation Analysis]
38 Lei ZB. Adverse reactions and rational use of proton pump inhibitors. Shijie Huaren Xiaohua Zazhi 2016; 24(23): 3468-3475 [DOI: 10.11569/wcjd.v24.i23.3468] [Reference Citation Analysis]
39 Amin AM, Omar MM, Abd-elhaliem SM, Elshanawany AA. Gastric ulcer localization: Potential use of 125I-omeprazole as radiotracer. Radiochemistry 2015;57:182-6. [DOI: 10.1134/s1066362215020113] [Cited by in Crossref: 5] [Article Influence: 0.7] [Reference Citation Analysis]
40 Csiki E, Szabó H, Hanák L, Szakács Z, Kiss S, Vörhendi N, Pécsi D, Hegyi E, Hegyi P, Erőss B. Oral Proton Pump Inhibitors May Be as Effective as Intravenous in Peptic Ulcer Bleeding: A Systematic Review and Meta-analysis. Clin Transl Gastroenterol 2021;12:e00341. [PMID: 33988530 DOI: 10.14309/ctg.0000000000000341] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Kim H, Hwang YS, Kim M, Park SB. Recent advances in the development of covalent inhibitors. RSC Med Chem 2021;12:1037-45. [PMID: 34355176 DOI: 10.1039/d1md00068c] [Reference Citation Analysis]
42 Mori H, Suzuki H. Role of Acid Suppression in Acid-related Diseases: Proton Pump Inhibitor and Potassium-competitive Acid Blocker. J Neurogastroenterol Motil. 2019;25:6-14. [PMID: 30504527 DOI: 10.5056/jnm18139] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
43 Patel A, Spychalski P, Antoszewska M, Regula J, Kobiela J. Proton pump inhibitors and colorectal cancer: A systematic review. World J Gastroenterol 2021; 27(44): 7716-7733 [PMID: 34908809 DOI: 10.3748/wjg.v27.i44.7716] [Reference Citation Analysis]
44 Kanagaratham C, El Ansari YS, Sallis BF, Hollister BA, Lewis OL, Minnicozzi SC, Oyoshi MK, Rosen R, Nurko S, Fiebiger E, Oettgen HC. Omeprazole inhibits IgE-mediated mast cell activation and allergic inflammation induced by ingested allergen in mice. J Allergy Clin Immunol 2020;146:884-893.e5. [PMID: 32194041 DOI: 10.1016/j.jaci.2020.02.032] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
45 Yepuri G, Sukhovershin R, Nazari-Shafti TZ, Petrascheck M, Ghebre YT, Cooke JP. Proton Pump Inhibitors Accelerate Endothelial Senescence. Circ Res 2016;118:e36-42. [PMID: 27166251 DOI: 10.1161/CIRCRESAHA.116.308807] [Cited by in Crossref: 63] [Cited by in F6Publishing: 25] [Article Influence: 10.5] [Reference Citation Analysis]
46 Lin HC, Hsiao YT, Lin HL, Uang YS, Cheng HW, Wang Y, Wang LH. The use of proton pump inhibitors decreases the risk of diabetes mellitus in patients with upper gastrointestinal disease: A population-based retrospective cohort study. Medicine (Baltimore) 2016;95:e4195. [PMID: 27428221 DOI: 10.1097/MD.0000000000004195] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
47 Tang C, Chen Z, Dai X, Zhu W, Zhong D, Chen X. Mechanism of Reductive Metabolism and Chiral Inversion of Proton Pump Inhibitors. Drug Metab Dispos 2019;47:657-64. [PMID: 30962289 DOI: 10.1124/dmd.118.086090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
48 Lazzerini PE, Cartocci A, Qu YS, Saponara S, Furini S, Fusi F, Fabris F, Gamberucci A, El-Sherif N, Cevenini G, Pettini F, Laghi-Pasini F, Acampa M, Bertolozzi I, Capecchi PL, Lazaro D, Boutjdir M. Proton Pump Inhibitors Directly Block hERG-Potassium Channel and Independently Increase the Risk of QTc Prolongation in a Large Cohort of US Veterans. Circ Arrhythm Electrophysiol 2021;14:e010042. [PMID: 34143643 DOI: 10.1161/CIRCEP.121.010042] [Reference Citation Analysis]
49 Li Q, Lei ZB. Combined use of proton pump inhibitors and prokinetics: Feasibility and cautions. Shijie Huaren Xiaohua Zazhi 2016; 24(18): 2856-2861 [DOI: 10.11569/wcjd.v24.i18.2856] [Reference Citation Analysis]
50 Sohn SH, Kim N, Jo HJ, Kim J, Park JH, Nam RH, Seok YJ, Kim YR, Lee DH. Analysis of Gastric Body Microbiota by Pyrosequencing: Possible Role of Bacteria Other Than Helicobacter pylori in the Gastric Carcinogenesis. J Cancer Prev. 2017;22:115-125. [PMID: 28698866 DOI: 10.15430/jcp.2017.22.2.115] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 5.2] [Reference Citation Analysis]
51 Ikemura K, Hiramatsu S, Okuda M. Drug Repositioning of Proton Pump Inhibitors for Enhanced Efficacy and Safety of Cancer Chemotherapy. Front Pharmacol. 2017;8:911. [PMID: 29311921 DOI: 10.3389/fphar.2017.00911] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
52 Lee YD, Kim SE, Park SJ, Park MI, Moon W, Kim JH, Jung K, Song J. Efficacy of Seven-day High-dose Esomeprazole-based Triple Therapy versus Seven-day Standard Dose Non-esomeprazole-based Triple Therapy as the First-line Treatment of Patients with Helicobacter pylori Infection. Korean J Gastroenterol 2020;76:142-9. [PMID: 32969362 DOI: 10.4166/kjg.2020.76.3.142] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
53 Mitini-Nkhoma SC, Fernando N, Ishaka GKD, Handunnetti SM, Pathirana SL. Ion Transport Modulators as Antimycobacterial Agents. Tuberc Res Treat 2020;2020:3767915. [PMID: 33294223 DOI: 10.1155/2020/3767915] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
54 Kumar A, Kumar R, Flanagan J, Långström B, Björndahl L, Darreh-Shori T. Esomeprazole reduces sperm motility index by targeting the spermic cholinergic machinery: A mechanistic study for the association between use of proton pump inhibitors and reduced sperm motility index. Biochem Pharmacol 2020;182:114212. [PMID: 32866455 DOI: 10.1016/j.bcp.2020.114212] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
55 Anastassova NO, Mavrova AT, Yancheva DY, Kondeva-burdina MS, Tzankova VI, Stoyanov SS, Shivachev BL, Nikolova RP. Hepatotoxicity and antioxidant activity of some new N,N′-disubstituted benzimidazole-2-thiones, radical scavenging mechanism and structure-activity relationship. Arabian Journal of Chemistry 2018;11:353-69. [DOI: 10.1016/j.arabjc.2016.12.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 4.8] [Reference Citation Analysis]
56 Hamada Y, Ikemura K, Iwamoto T, Okuda M. Stereoselective Inhibition of Renal Basolateral Human Organic Anion Transporter 3 by Lansoprazole Enantiomers. Pharmacology 2018;101:176-83. [PMID: 29353278 DOI: 10.1159/000485920] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
57 Li Y, Ren BX, Li HM, Lu T, Fu R, Wu ZQ. Omeprazole suppresses aggressive cancer growth and metastasis in mice through promoting Snail degradation. Acta Pharmacol Sin 2021. [PMID: 34785782 DOI: 10.1038/s41401-021-00787-1] [Reference Citation Analysis]
58 Sachs G, Marcus EA, Wen Y, Munson K. Editorial: control of acid secretion. Aliment Pharmacol Ther 2018;48:682-3. [PMID: 30132940 DOI: 10.1111/apt.14864] [Reference Citation Analysis]
59 Ha VH, Ngo M, Chu MP, Ghosh S, Sawyer MB, Chambers CR. Does gastric acid suppression affect sunitinib efficacy in patients with advanced or metastatic renal cell cancer? J Oncol Pharm Pract 2015;21:194-200. [DOI: 10.1177/1078155214527145] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
60 Nallapeta N, Reynolds JL, Bakhai S. Deprescribing Proton Pump Inhibitors in an Academic, Primary Care Clinic: Quality Improvement Project. J Clin Gastroenterol 2020;54:864-70. [PMID: 32091449 DOI: 10.1097/MCG.0000000000001317] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
61 Shiraev TP, Bullen A. Proton Pump Inhibitors and Cardiovascular Events: A Systematic Review. Heart Lung Circ 2018;27:443-50. [PMID: 29233498 DOI: 10.1016/j.hlc.2017.10.020] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 5.4] [Reference Citation Analysis]
62 Strickland M, Nyenhuis D, Watanabe SM, Tjandra N, Carter CA. Novel Tsg101 Binding Partners Regulate Viral L Domain Trafficking. Viruses 2021;13:1147. [PMID: 34203832 DOI: 10.3390/v13061147] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
63 Min YW, Lee YC, Kim K, Ryu S, Hong KS, Jeon HH, Kim YS, Park JH, Son HJ, Rhee PL. Proton pump inhibitor use is associated with hip fracture development: a nationwide population-based cohort study. Korean J Intern Med 2020;35:1084-93. [PMID: 31671930 DOI: 10.3904/kjim.2018.331] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
64 Chiu KW, Nakano T, Chen KD, Hsu LW, Lai CY, Huang CY, Cheng YF, Goto S, Chen CL. Cytochrome P450 in living donor liver transplantation. J Biomed Sci 2015;22:32. [PMID: 25975271 DOI: 10.1186/s12929-015-0140-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
65 Kim KN, Yang SW, Kim H, Kwak SS, Kim YS, Cho DY. Acid Inhibitory Effect of a Combination of Omeprazole and Sodium Bicarbonate (CDFR0209) Compared With Delayed-Release Omeprazole 40 mg Alone in Healthy Adult Male Subjects. Clin Pharmacol Drug Dev 2018;7:53-8. [PMID: 28111929 DOI: 10.1002/cpdd.331] [Reference Citation Analysis]
66 Lilly CM, Aljawadi M, Badawi O, Onukwugha E, Tom SE, Magder LS, Harris I. Comparative Effectiveness of Proton Pump Inhibitors vs Histamine Type 2 Receptor Blockers for Preventing Clinically Important Gastrointestinal Bleeding During Intensive Care: A Population-Based Study. Chest 2018;154:557-66. [PMID: 29856970 DOI: 10.1016/j.chest.2018.05.015] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
67 Jia R, Zhang F, Wu N, Xu W, Gao H, Liu B, Wang H. Accelerating Development of Benziamidazole-Class Proton Pump Inhibitors: A Mechanism-Based PK/PD Model to Optimize Study Design with Ilaprazole as a Case Drug. Pharmaceutics 2021;13:392. [PMID: 33804279 DOI: 10.3390/pharmaceutics13030392] [Reference Citation Analysis]
68 Fais S, Marunaka Y. The Acidic Microenvironment: Is It a Phenotype of All Cancers? A Focus on Multiple Myeloma and Some Analogies with Diabetes Mellitus. Cancers (Basel) 2020;12:E3226. [PMID: 33147695 DOI: 10.3390/cancers12113226] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
69 Tchernookova BK, Gongwer MW, George A, Goeglein B, Powell AM, Caringal HL, Leuschner T, Phillips AG, Schantz AW, Kiedrowski L, Chappell R, Kreitzer MA, Malchow RP. ATP-mediated increase in H+ flux from retinal Müller cells: a role for Na+/H+ exchange. J Neurophysiol 2021;125:184-98. [PMID: 33206577 DOI: 10.1152/jn.00546.2020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
70 Niece KL, Boyd NK, Akers KS. In vitro study of the variable effects of proton pump inhibitors on voriconazole. Antimicrob Agents Chemother 2015;59:5548-54. [PMID: 26124167 DOI: 10.1128/AAC.00884-15] [Cited by in Crossref: 22] [Cited by in F6Publishing: 9] [Article Influence: 3.1] [Reference Citation Analysis]
71 Tachibana M, Hanaoka T, Watanabe S, Matsushita M, Isono T, Tsutsumi Y. Colitis nucleomigrans: The third type of microscopic colitis (part 1). Pathol Int 2020;70:752-60. [PMID: 32761850 DOI: 10.1111/pin.12996] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
72 Burger M, Schmitt-Koopmann C, Leroux JC. DNA unchained: two assays to discover and study inhibitors of the DNA clustering function of barrier-to-autointegration factor. Sci Rep 2020;10:12301. [PMID: 32704141 DOI: 10.1038/s41598-020-69246-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
73 Zhao X, Zhang N, Huang Y, Dou X, Peng X, Wang W, Zhang Z, Wang R, Qiu Y, Jin M, Kong D. Lansoprazole Alone or in Combination With Gefitinib Shows Antitumor Activity Against Non-small Cell Lung Cancer A549 Cells in vitro and in vivo. Front Cell Dev Biol 2021;9:655559. [PMID: 33959611 DOI: 10.3389/fcell.2021.655559] [Reference Citation Analysis]
74 Chen Z, Gan F, Rao X, Huang X, Chen H. Pharmacokinetics, Bioequivalence, and Safety Studies of Pantoprazole Sodium Enteric-Coated Tablets in Healthy Subjects. Clin Pharmacol Drug Dev 2021;10:502-9. [PMID: 33128847 DOI: 10.1002/cpdd.888] [Reference Citation Analysis]
75 Lau YY, Gu W, Lin T, Viraswami-Appanna K, Cai C, Scott JW, Shi M. Assessment of drug-drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer. Cancer Chemother Pharmacol 2017;79:1119-28. [PMID: 28424965 DOI: 10.1007/s00280-017-3308-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
76 Thong BKS, Ima-Nirwana S, Chin KY. Proton Pump Inhibitors and Fracture Risk: A Review of Current Evidence and Mechanisms Involved. Int J Environ Res Public Health 2019;16:E1571. [PMID: 31060319 DOI: 10.3390/ijerph16091571] [Cited by in Crossref: 33] [Cited by in F6Publishing: 22] [Article Influence: 11.0] [Reference Citation Analysis]
77 Sukhovershin RA, Cooke JP. How May Proton Pump Inhibitors Impair Cardiovascular Health? Am J Cardiovasc Drugs 2016;16:153-61. [PMID: 26817947 DOI: 10.1007/s40256-016-0160-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 4.4] [Reference Citation Analysis]
78 Sugano K. Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date. Therap Adv Gastroenterol. 2018;11:1756283X17745776. [PMID: 29383028 DOI: 10.1177/1756283x17745776] [Cited by in Crossref: 33] [Cited by in F6Publishing: 12] [Article Influence: 8.3] [Reference Citation Analysis]
79 Saito J, Yakuwa N, Sandaiji N, Kawasaki H, Kaneko K, Suzuki T, Yamatani A, Sago H, Murashima A. Esomeprazole During Pregnancy and Lactation: Esomeprazole Levels in Maternal Serum, Cord Blood, Breast Milk, and the Infant's Serum. Breastfeed Med 2020;15:598-601. [PMID: 32635742 DOI: 10.1089/bfm.2020.0175] [Reference Citation Analysis]
80 Apostu D, Lucaciu O, Lucaciu GD, Crisan B, Crisan L, Baciut M, Onisor F, Baciut G, Câmpian RS, Bran S. Systemic drugs that influence titanium implant osseointegration. Drug Metab Rev 2017;49:92-104. [PMID: 28030966 DOI: 10.1080/03602532.2016.1277737] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 7.8] [Reference Citation Analysis]
81 Canitano A, Iessi E, Spugnini EP, Federici C, Fais S. Proton pump inhibitors induce a caspase-independent antitumor effect against human multiple myeloma. Cancer Lett 2016;376:278-83. [PMID: 27084522 DOI: 10.1016/j.canlet.2016.04.015] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 6.5] [Reference Citation Analysis]
82 Serratice M, Bertrand B, Janssen EFJ, Hemelt E, Zucca A, Cocco F, Cinellu MA, Casini A. Gold( i ) compounds with lansoprazole-type ligands: synthesis, characterization and anticancer properties in vitro. Med Chem Commun 2014;5:1418-22. [DOI: 10.1039/c4md00241e] [Cited by in Crossref: 5] [Article Influence: 0.6] [Reference Citation Analysis]
83 Shakhnovich V, Smith PB, Guptill JT, James LP, Collier DN, Wu H, Livingston CE, Zhao J, Kearns GL; Best Pharmaceuticals for Children Act – Pediatric Trials Network. Obese Children Require Lower Doses of Pantoprazole Than Nonobese Peers to Achieve Equal Systemic Drug Exposures. J Pediatr 2018;193:102-108.e1. [PMID: 29389444 DOI: 10.1016/j.jpeds.2017.10.011] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
84 Hussain MS, Mazumder T. Long-term use of proton pump inhibitors adversely affects minerals and vitamin metabolism, bone turnover, bone mass, and bone strength. J Basic Clin Physiol Pharmacol 2021. [PMID: 34687598 DOI: 10.1515/jbcpp-2021-0203] [Reference Citation Analysis]
85 Song Y, Dou F, Zhou Z, Yang N, Zhong J, Pan J, Liu Q, Zhang J, Wang S. Microarray-Based Detection and Clinical Evaluation for Helicobacter pylori Resistance to Clarithromycin or Levofloxacin and the Genotype of CYP2C19 in 1083 Patients. Biomed Res Int 2018;2018:2684836. [PMID: 30276203 DOI: 10.1155/2018/2684836] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
86 Toda R, Miyagawa T, Masuda Y, Hoshino Y, Yoshii K, Hirayama M, Shibuya M, Kawabata Y. Mass balance and metabolism of Z-215, a novel proton pump inhibitor, in healthy volunteers. Xenobiotica 2018;48:1006-20. [PMID: 29092680 DOI: 10.1080/00498254.2017.1390625] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
87 Ortiz-Guerrero G, Amador-Muñoz D, Calderón-Ospina CA, López-Fuentes D, Nava Mesa MO. Proton Pump Inhibitors and Dementia: Physiopathological Mechanisms and Clinical Consequences. Neural Plast 2018;2018:5257285. [PMID: 29755512 DOI: 10.1155/2018/5257285] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
88 Tonazzi A, Eberini I, Indiveri C. Molecular mechanism of inhibition of the mitochondrial carnitine/acylcarnitine transporter by omeprazole revealed by proteoliposome assay, mutagenesis and bioinformatics. PLoS One 2013;8:e82286. [PMID: 24349247 DOI: 10.1371/journal.pone.0082286] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
89 Hálfdánarson ÓÖ, Fall K, Ogmundsdottir MH, Lund SH, Steingrímsson E, Ogmundsdottir HM, Zoega H. Proton pump inhibitor use and risk of breast cancer, prostate cancer, and malignant melanoma: An Icelandic population‐based case‐control study. Pharmacoepidemiol Drug Saf 2019;28:471-8. [DOI: 10.1002/pds.4702] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
90 Aslan M, Celik Y, Karadas S, Olmez S, Cifci A. Liver hepatotoxicity associated with pantoprazole: a rare case report. Wien Klin Wochenschr 2014;126:390-2. [PMID: 24652021 DOI: 10.1007/s00508-014-0535-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
91 Mitini-Nkhoma SC, Fernando N, Ishaka GKD, Handunnetti SM, Pathirana SL. Ion Transport Modulators Differentially Modulate Inflammatory Responses in THP-1-Derived Macrophages. J Immunol Res 2021;2021:8832586. [PMID: 33928172 DOI: 10.1155/2021/8832586] [Reference Citation Analysis]
92 Surur AS, Schulig L, Link A. Interconnection of sulfides and sulfoxides in medicinal chemistry. Arch Pharm Chem Life Sci . [DOI: 10.1002/ardp.201800248] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
93 Helgadóttir H, Lund SH, Gizurarson S, Waldum H, Björnsson ES. Pharmacokinetics of single and repeated oral doses of esomeprazole and gastrin elevation in healthy males and females. Scand J Gastroenterol 2021;56:128-36. [PMID: 33327801 DOI: 10.1080/00365521.2020.1859610] [Reference Citation Analysis]
94 Liu NN, Köhler JR. Antagonism of Fluconazole and a Proton Pump Inhibitor against Candida albicans. Antimicrob Agents Chemother 2016;60:1145-7. [PMID: 26596946 DOI: 10.1128/AAC.02043-15] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
95 Pape E, Michel D, Scala-Bertola J, Schiestel T, Harlé A, Bouchet S, Contet A, Pochon C, Gambier N. Effect of esomeprazole on the oral absorption of dasatinib in a patient with Philadelphia-positive acute lymphoblastic leukemia. Br J Clin Pharmacol 2016;81:1195-6. [PMID: 26833554 DOI: 10.1111/bcp.12895] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
96 Suherman LP, Kartidjo P, Rukmawati I, Septiani V, Azzura F. Dyspepsia Drug Use Pattern of Outpatients in a Public Health Center in Batununggal District Bandung. Borneo J Pharm 2021;4:345-54. [DOI: 10.33084/bjop.v4i4.1987] [Reference Citation Analysis]
97 AbdElhalim MS, Kenawy AS, Demellawy HHE, Azouz AA, Alghanem SS, Al-Otaibi T, Gheith O, ElMonem MA, Afifi MK, Hussein RRS. The impact of omeprazole on mycophenolate pharmacokinetics in kidney transplant recipients. Kidney Res Clin Pract 2020;39:479-86. [PMID: 33214342 DOI: 10.23876/j.krcp.20.059] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
98 [DOI: 10.1101/2020.05.04.075036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
99 Šutalo S, Ruetten M, Hartnack S, Reusch CE, Kook PH. The effect of orally administered ranitidine and once-daily or twice-daily orally administered omeprazole on intragastric pH in cats. J Vet Intern Med 2015;29:840-6. [PMID: 25966746 DOI: 10.1111/jvim.12580] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
100 Basagni F, Rosini M, Decker M. Functionalized Cannabinoid Subtype 2 Receptor Ligands: Fluorescent, PET, Photochromic and Covalent Molecular Probes. ChemMedChem 2020;15:1374-89. [PMID: 32578963 DOI: 10.1002/cmdc.202000298] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
101 Frye JW, Peura DA. Managing gastroesophageal reflux disease - comparative efficacy and outcomes of dexlansoprazole MR. Ther Clin Risk Manag 2015;11:1649-56. [PMID: 26586949 DOI: 10.2147/TCRM.S66680] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
102 Liu D, Yang H, Jiang J, Nagy P, Shen K, Qian J, Hu P. Pharmacokinetic and Pharmacodynamic Modeling Analysis of Intravenous Esomeprazole in Healthy Volunteers. J Clin Pharmacol 2016;56:816-26. [PMID: 26970404 DOI: 10.1002/jcph.733] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
103 Xu WT, Xu XB, Ren TS, Qi XS. Vonoprazan for treatment of gastroesophageal reflux disease: Research advances. Shijie Huaren Xiaohua Zazhi 2021; 29(21): 1248-1253 [DOI: 10.11569/wcjd.v29.i21.1248] [Reference Citation Analysis]
104 [DOI: 10.1101/2020.04.03.024257] [Cited by in Crossref: 35] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
105 Kukulka M, Nudurupati S, Perez MC. Bioavailability, safety, and pharmacodynamics of delayed-release dexlansoprazole administered as two 30 mg orally disintegrating tablets or one 60 mg capsule. Therap Adv Gastroenterol 2016;9:770-80. [PMID: 27803732 DOI: 10.1177/1756283X16666800] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
106 Choi YJ, Kim N, Jang IJ, Cho JY, Nam RH, Park JH, Jo HJ, Yoon H, Shin CM, Park YS, Lee DH, Jung HC. Pantoprazole Does Not Reduce the Antiplatelet Effect of Clopidogrel: A Randomized Controlled Trial in Korea. Gut Liver 2017;11:504-11. [PMID: 28395507 DOI: 10.5009/gnl16352] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
107 Watanabe SM, Ehrlich LS, Strickland M, Li X, Soloveva V, Goff AJ, Stauft CB, Bhaduri-McIntosh S, Tjandra N, Carter C. Selective Targeting of Virus Replication by Proton Pump Inhibitors. Sci Rep 2020;10:4003. [PMID: 32132561 DOI: 10.1038/s41598-020-60544-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
108 Taneja G, Thanikachalam PV, Rajput SK. Dose and time-dependent toxicological impact of pantoprazole on vascular endothelium and renal tissue. Toxicol Lett 2020;333:97-104. [PMID: 32763312 DOI: 10.1016/j.toxlet.2020.07.031] [Reference Citation Analysis]
109 Yu M, Lee C, Wang M, Tannock IF. Influence of the proton pump inhibitor lansoprazole on distribution and activity of doxorubicin in solid tumors. Cancer Sci 2015;106:1438-47. [PMID: 26212113 DOI: 10.1111/cas.12756] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.1] [Reference Citation Analysis]
110 Granja S, Tavares-Valente D, Queirós O, Baltazar F. Value of pH regulators in the diagnosis, prognosis and treatment of cancer. Semin Cancer Biol 2017;43:17-34. [PMID: 28065864 DOI: 10.1016/j.semcancer.2016.12.003] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 10.0] [Reference Citation Analysis]
111 Kukulka M, Nudurupati S, Perez MC. Pharmacokinetics and pharmacodynamics of an orally disintegrating tablet formulation of dexlansoprazole. Therap Adv Gastroenterol 2016;9:759-69. [PMID: 27803731 DOI: 10.1177/1756283X16670073] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
112 Marinescu M. Synthesis of Antimicrobial Benzimidazole-Pyrazole Compounds and Their Biological Activities. Antibiotics (Basel) 2021;10:1002. [PMID: 34439052 DOI: 10.3390/antibiotics10081002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
113 Woodland P, Amarasinghe G, Sifrim D. Emerging therapeutic options in GERD. Best Practice & Research Clinical Gastroenterology 2013;27:455-67. [DOI: 10.1016/j.bpg.2013.06.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
114 Ivashkin VT, Maev IV, Trukhmanov AS, Lapina TL, Storonova OA, Zayratyants OV, Dronova OB, Kucheryavyy YA, Pirogov SS, Sayfutdinov RG, Uspenskiy YP, Sheptulin AA, Andreev DN, Rumyantseva DE. Recommendations of the Russian Gastroenterological Association in Diagnosis and Treatment of Gastroesophageal Reflux Disease. Rossijskij žurnal gastroènterologii, gepatologii, koloproktologii 2020;30:70-97. [DOI: 10.22416/1382-4376-2020-30-4-70-97] [Cited by in Crossref: 17] [Cited by in F6Publishing: 1] [Article Influence: 8.5] [Reference Citation Analysis]
115 Yu D, Zhang Q, De Jaegher B, Liu J, Sui Q, Zheng X, Wei Y. Effect of proton pump inhibitor on microbial community, function, and kinetics in anaerobic digestion with ammonia stress. Bioresour Technol 2021;319:124118. [PMID: 32957047 DOI: 10.1016/j.biortech.2020.124118] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
116 Asdaq SMB, ALbasha M, Almutairi A, Alyabisi R, Almuhaisni A, Faqihi R, Alamri AS, Alsanie WF, Alhomrani M. Use of proton pump inhibitors: An exploration of awareness, attitude and behavior of health care professionals of Riyadh, Saudi Arabia. Saudi Pharm J 2021;29:713-8. [PMID: 34400866 DOI: 10.1016/j.jsps.2021.04.033] [Reference Citation Analysis]
117 Arshad T, Khan KM, Rasool N, Salar U, Hussain S, Asghar H, Ashraf M, Wadood A, Riaz M, Perveen S, Taha M, Ismail NH. 5-Bromo-2-aryl benzimidazole derivatives as non-cytotoxic potential dual inhibitors of α -glucosidase and urease enzymes. Bioorganic Chemistry 2017;72:21-31. [DOI: 10.1016/j.bioorg.2017.03.007] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 6.4] [Reference Citation Analysis]
118 Race C, Chowdry J, Russell JM, Corfe BM, Riley SA. Studies of salivary pepsin in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2019;49:1173-80. [PMID: 30977177 DOI: 10.1111/apt.15138] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
119 Darroudi M, Mohammadi Ziarani G, Bahar S, Ghasemi JB, Badiei A. Lansoprazole-Based Colorimetric Chemosensor for Efficient Binding and Sensing of Carbonate Ion: Spectroscopy and DFT Studies. Front Chem 2020;8:626472. [PMID: 33604329 DOI: 10.3389/fchem.2020.626472] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
120 Martin JS, MacKenzie CJ, Fletcher D, Gilbert IH. Characterising covalent warhead reactivity. Bioorg Med Chem 2019;27:2066-74. [PMID: 30975501 DOI: 10.1016/j.bmc.2019.04.002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
121 Bhattacharya S, Khanam J, Sarkar P, Pal TK. A chemotherapeutic approach targeting the acidic tumor microenvironment: combination of a proton pump inhibitor and paclitaxel for statistically optimized nanotherapeutics. RSC Adv 2019;9:240-54. [DOI: 10.1039/c8ra08924h] [Cited by in Crossref: 6] [Article Influence: 2.0] [Reference Citation Analysis]
122 Jo Y, Park E, Ahn SB, Jo YK, Son B, Kim SH, Park YS, Kim HJ. A Proton Pump Inhibitor's Effect on Bone Metabolism Mediated by Osteoclast Action in Old Age: A Prospective Randomized Study. Gut Liver 2015;9:607-14. [PMID: 25473078 DOI: 10.5009/gnl14135] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
123 Michaelis M, Kleinschmidt MC, Bojkova D, Rabenau HF, Wass MN, Cinatl J Jr. Omeprazole Increases the Efficacy of Acyclovir Against Herpes Simplex Virus Type 1 and 2. Front Microbiol 2019;10:2790. [PMID: 31849920 DOI: 10.3389/fmicb.2019.02790] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
124 Benchamana A, Mori H, MacDougald OA, Soodvilai S. Regulation of adipocyte differentiation and metabolism by lansoprazole. Life Sci 2019;239:116897. [PMID: 31644894 DOI: 10.1016/j.lfs.2019.116897] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
125 Soulère L, Barbier T, Queneau Y. Docking-based virtual screening studies aiming at the covalent inhibition of SARS-CoV-2 MPro by targeting the cysteine 145. Comput Biol Chem 2021;92:107463. [PMID: 33677227 DOI: 10.1016/j.compbiolchem.2021.107463] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
126 Oh JH, Kang D, Kang W, Guallar E, Cho J, Min YW. Proton Pump Inhibitor Use Increases Pyogenic Liver Abscess Risk: A Nationwide Cohort Study. J Neurogastroenterol Motil 2021;27:555-64. [PMID: 34642276 DOI: 10.5056/jnm20221] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
127 Choo BK, Roh SS. Berberine protects against esophageal mucosal damage in reflux esophagitis by suppressing proinflammatory cytokines. Exp Ther Med. 2013;6:663-670. [PMID: 24137243 DOI: 10.3892/etm.2013.1202] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
128 Sui X, Guan J, Li X, Gu L, Yan F, Shi S, Zhang D. Preparation of a polydopamine/β-cyclodextrin coated open tubular capillary electrochromatography column and application for enantioseparation of five proton pump inhibitors. J Sep Sci 2021;44:3295-304. [PMID: 34185396 DOI: 10.1002/jssc.202100298] [Reference Citation Analysis]
129 Niu L, Liu Y, Hou X, Cui L, Li J, Zhang X, Zhang M. Extracellular acidosis contracts coronary but neither renal nor mesenteric artery via modulation of H + ,K + -ATPase, voltage-gated K + channels and L-type Ca 2+ channels: Extracellular acidosis contracts rat coronary artery. Exp Physiol 2014;99:995-1006. [DOI: 10.1113/expphysiol.2014.078634] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
130 Gomez-Ramirez U, Valencia-Mayoral P, Mendoza-Elizalde S, Murillo-Eliosa JR, Solórzano Santos F, Contreras-Rodríguez A, Zúñiga G, Aguilar-Rodea P, Jiménez-Rojas VL, Vigueras Galindo JC, Salazar-García M, Velázquez-Guadarrama N. Role of Helicobacter pylori and Other Environmental Factors in the Development of Gastric Dysbiosis. Pathogens 2021;10:1203. [PMID: 34578235 DOI: 10.3390/pathogens10091203] [Reference Citation Analysis]
131 Rahman S, Rahman T. Unveiling some FDA-approved drugs as inhibitors of the store-operated Ca2+ entry pathway. Sci Rep 2017;7. [DOI: 10.1038/s41598-017-13343-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 5.2] [Reference Citation Analysis]
132 Gabrielsson J, Hjorth S. Integration of Pharmacokinetic and Pharmacodynamic Reasoning and Its Importance in Drug Discovery. In: Giordanetto FG, editor. Early Drug Development. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA; 2018. pp. 367-98. [DOI: 10.1002/9783527801756.ch14] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
133 Tommasi S, Elliot DJ, Hulin JA, Lewis BC, McEvoy M, Mangoni AA. Human dimethylarginine dimethylaminohydrolase 1 inhibition by proton pump inhibitors and the cardiovascular risk marker asymmetric dimethylarginine: in vitro and in vivo significance. Sci Rep 2017;7:2871. [PMID: 28588208 DOI: 10.1038/s41598-017-03069-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
134 Chwiesko A, Charkiewicz R, Niklinski J, Luczaj W, Skrzydlewska E, Milewski R, Baniukiewicz A, Wroblewski E, Rosolowski M, Dabrowski A. Effects of different omeprazole dosing on gastric pH in non-variceal upper gastrointestinal bleeding: A randomized prospective study: Omeprazole in gastrointestinal bleeding. Journal of Digestive Diseases 2016;17:588-99. [DOI: 10.1111/1751-2980.12393] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
135 Inatomi N, Matsukawa J, Sakurai Y, Otake K. Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases. Pharmacol Ther. 2016;168:12-22. [PMID: 27514776 DOI: 10.1016/j.pharmthera.2016.08.001] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 6.8] [Reference Citation Analysis]
136 Wang H, Sun Y, Yang Y, Guo W, Zheng M, Zhang W, Fawcett JP, Gu J. Application of a high-throughput, parallel HPLC system for quantitative chiral analysis of pantoprazole. Bioanalysis 2015;7:2981-90. [DOI: 10.4155/bio.15.215] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
137 Abdul-hussein M, Freeman J, Castell D. Concomitant Administration of a Histamine 2 Receptor Antagonist and Proton Pump Inhibitor Enhances Gastric Acid Suppression. Pharmacotherapy 2015;35:1124-9. [DOI: 10.1002/phar.1665] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
138 Sakurai Y, Shiino M, Okamoto H, Nishimura A, Nakamura K, Hasegawa S. Pharmacokinetics and Safety of Triple Therapy with Vonoprazan, Amoxicillin, and Clarithromycin or Metronidazole: A Phase 1, Open-Label, Randomized, Crossover Study. Adv Ther 2016;33:1519-35. [DOI: 10.1007/s12325-016-0374-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
139 Jonaitis P, Jonaitis L, Kupcinskas J. Role of Genetic Polymorphisms of Cytochrome P450 2C19 in Pantoprazole Metabolism and Pantoprazole-based Helicobacter pylori Eradication Regimens. Curr Drug Metab. 2020;. [PMID: 32407266 DOI: 10.2174/1389200221666200514081442] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
140 Bosnjak T, Solberg R, Hemati PD, Jafari A, Kassem M, Johansen HT. Lansoprazole inhibits the cysteine protease legumain by binding to the active site. Basic Clin Pharmacol Toxicol 2019;125:89-99. [PMID: 30916878 DOI: 10.1111/bcpt.13230] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
141 Morschel CF, Mafra D, Eduardo JCC. The relationship between proton pump inhibitors and renal disease. J Bras Nefrol 2018;40:301-6. [PMID: 30010692 DOI: 10.1590/2175-8239-jbn-2018-0021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
142 Albatany M, Ostapchenko VG, Meakin S, Bartha R. Brain tumor acidification using drugs simultaneously targeting multiple pH regulatory mechanisms. J Neurooncol 2019;144:453-62. [PMID: 31392597 DOI: 10.1007/s11060-019-03251-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
143 Ruiz-Garcia A, Masters JC, Mendes da Costa L, LaBadie RR, Liang Y, Ni G, Ellery CA, Boutros T, Goldberg Z, Bello CL. Effect of food or proton pump inhibitor treatment on the bioavailability of dacomitinib in healthy volunteers. J Clin Pharmacol 2016;56:223-30. [PMID: 26179237 DOI: 10.1002/jcph.588] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
144 Ghim JL, Chin MC, Jung J, Lee J, Kim S, Kim B, Song GS, Choi YK, Shin JG. Pharmacokinetics and Pharmacodynamics of Tegoprazan Coadministered With Amoxicillin and Clarithromycin in Healthy Subjects. J Clin Pharmacol 2021;61:913-22. [PMID: 33341955 DOI: 10.1002/jcph.1805] [Reference Citation Analysis]
145 Estrada-Ortiz N, Lopez-Gonzales E, Woods B, Stürup S, de Graaf IAM, Groothuis GMM, Casini A. Ex vivo toxicological evaluation of experimental anticancer gold(i) complexes with lansoprazole-type ligands. Toxicol Res (Camb) 2019;8:885-95. [PMID: 32190293 DOI: 10.1039/c9tx00149b] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
146 Ray A, Sharma S, Sadasivam B. The Potential Therapeutic Role of Proton Pump Inhibitors in COVID-19: Hypotheses Based on Existing Evidences. Drug Res (Stuttg). 2020;70:484-488. [PMID: 32877948 DOI: 10.1055/a-1236-3041] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
147 Namdev A, Jain D. Floating Drug Delivery Systems: An Emerging Trend for the Treatment of Peptic Ulcer. Curr Drug Deliv 2019;16:874-86. [PMID: 31894738 DOI: 10.2174/1567201816666191018163519] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
148 Soleymani S, Bahramsoltani R, Rahimi R, Abdollahi M. Clinical risks of St John’s Wort ( Hypericum perforatum ) co-administration. Expert Opinion on Drug Metabolism & Toxicology 2017;13:1047-62. [DOI: 10.1080/17425255.2017.1378342] [Cited by in Crossref: 43] [Cited by in F6Publishing: 27] [Article Influence: 8.6] [Reference Citation Analysis]
149 Chang H, Chang Y, Wang K, Cheng T, Tsai H. Esomeprazole‐induced ashy dermatosis‐like drug eruptions. Australas J Dermatol 2019;60. [DOI: 10.1111/ajd.12978] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
150 Cucchi D, Menon A, Feroldi FM, Boerci L, Randelli PS. The presence of gastroesophageal reflux disease increases the risk of developing postoperative shoulder stiffness after arthroscopic rotator cuff repair. J Shoulder Elbow Surg 2020;29:2505-13. [PMID: 32711105 DOI: 10.1016/j.jse.2020.07.002] [Reference Citation Analysis]
151 Mehanna MM, Mneimneh AT, Domiati S, Allam AN. Tadalafil-Loaded Limonene-Based Orodispersible Tablets: Formulation, in vitro Characterization and in vivo Appraisal of Gastroprotective Activity. Int J Nanomedicine 2020;15:10099-112. [PMID: 33363369 DOI: 10.2147/IJN.S288552] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
152 Zhou S, Skaar DJ, Jacobson PA, Huang RS. Pharmacogenomics of Medications Commonly Used in the Intensive Care Unit. Front Pharmacol 2018;9:1436. [PMID: 30564130 DOI: 10.3389/fphar.2018.01436] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
153 Mester A, Apostu D, Ciobanu L, Piciu A, Lucaciu O, Campian RS, Taulescu M, Bran S. The impact of proton pump inhibitors on bone regeneration and implant osseointegration. Drug Metab Rev 2019;51:330-9. [PMID: 31055956 DOI: 10.1080/03602532.2019.1610767] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
154 Shibany KA, Pratt SL, Aldurdunji M, Totemeyer S, Paine SW. Prediction of pharmacokinetic clearance and potential Drug-Drug interactions for omeprazole in the horse using in vitro systems. Xenobiotica 2020;50:1220-7. [PMID: 32369392 DOI: 10.1080/00498254.2020.1764131] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
155 Guzman-Prado Y, Vita R, Samson O. Concomitant Use of Levothyroxine and Proton Pump Inhibitors in Patients with Primary Hypothyroidism: a Systematic Review. J Gen Intern Med 2021;36:1726-33. [PMID: 33469743 DOI: 10.1007/s11606-020-06403-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
156 Kumar R, Kumar A, Nordberg A, Långström B, Darreh-Shori T. Proton pump inhibitors act with unprecedented potencies as inhibitors of the acetylcholine biosynthesizing enzyme-A plausible missing link for their association with incidence of dementia. Alzheimers Dement 2020;16:1031-42. [PMID: 32383816 DOI: 10.1002/alz.12113] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
157 Lugini L, Federici C, Borghi M, Azzarito T, Marino ML, Cesolini A, Spugnini EP, Fais S. Proton pump inhibitors while belonging to the same family of generic drugs show different anti-tumor effect. J Enzyme Inhib Med Chem 2016;31:538-45. [PMID: 26018420 DOI: 10.3109/14756366.2015.1046062] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.6] [Reference Citation Analysis]
158 Leis J, Luan CH, Audia JE, Dunne SF, Heath CM. Ilaprazole and other novel prazole-based compounds that bind Tsg101 inhibit viral budding of HSV-1/2 and HIV from cells. J Virol 2021:JVI. [PMID: 33731460 DOI: 10.1128/JVI.00190-21] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
159 ElObeid AS, Haseeb A. Treating ENT symptoms and diseases induced by extraesophageal acidity using plant extracted melanin. Med Hypotheses 2020;144:110126. [PMID: 32758902 DOI: 10.1016/j.mehy.2020.110126] [Reference Citation Analysis]
160 Porayette P, Flockhart D, Gupta SK. One size fits one: pharmacogenetics in gastroenterology. Clin Gastroenterol Hepatol 2014;12:565-70. [PMID: 24486737 DOI: 10.1016/j.cgh.2014.01.035] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
161 Wiesner A, Zwolińska-Wcisło M, Paśko P. Effect of Food and Dosing Regimen on Safety and Efficacy of Proton Pump Inhibitors Therapy-A Literature Review. Int J Environ Res Public Health 2021;18:3527. [PMID: 33805341 DOI: 10.3390/ijerph18073527] [Reference Citation Analysis]
162 Oshima T, Miwa H. Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases. J Neurogastroenterol Motil. 2018;24:334-344. [PMID: 29739175 DOI: 10.5056/jnm18029] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
163 Shim YK, Kim N. The Effect of H2 Receptor Antagonist in Acid Inhibition and Its Clinical Efficacy. Korean J Gastroenterol 2017;70:4-12. [PMID: 28728310 DOI: 10.4166/kjg.2017.70.1.4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
164 Xie YL, Huang QC. Advances in prevention and treatment of chemotherapy-induced gastrointestinal mucositis with proton pump inhibitors. Shijie Huaren Xiaohua Zazhi 2014; 22(5): 642-647 [DOI: 10.11569/wcjd.v22.i5.642] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
165 Yan M, Wu ZF, Tang D, Wang F, Xiao YW, Xu P, Zhang BK, Liu YP, Xiang DX, Banh HL. The impact of proton pump inhibitors on the pharmacokinetics of voriconazole in vitro and in vivo. Biomed Pharmacother 2018;108:60-4. [PMID: 30216801 DOI: 10.1016/j.biopha.2018.08.121] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
166 Zhan SK, Wu XQ, Zheng FP. Clinical Characteristics and Manifestations of Fungal Esophagitis: A Single-Center Experience in South China. Gastroenterol Res Pract 2021;2021:8869494. [PMID: 33531895 DOI: 10.1155/2021/8869494] [Reference Citation Analysis]